No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the exploration, advancement, and marketing of innovative therapies rooted in RNA interference (RNAi) technology. The company's research pipeline for RNAi treatments targets a diverse array of medical conditions, encompassing inherited disorders, cardiovascular and metabolic diseases, hepatic infections, and illnesses affecting the central nervous system (CNS) and eyes. Alnylam's commercialized products include ONPATTRO (patisiran), an injectable lipid complex prescribed for adults experiencing polyneuropathy due to hereditary transthyretin-mediated amyloidosis. Also marketed are GIVLAARI, used to treat acute hepatic porphyria (AHP) in adult patients, and OXLUMO (lumasiran), indicated for primary hyperoxaluria type 1 (PH1). In terms of its developmental programs, the company is progressing several candidates: Givosiran, for the treatment of AHP in adolescent patients. Patisiran, being investigated for transthyretin amyloidosis (ATTR amyloidosis) when accompanied by cardiomyopathy. Cemdisiran, aimed at complement-mediated diseases. ALN-AAT02, for liver disease associated with AAT deficiency. ALN-HBV02, targeting chronic hepatitis B virus infection. Zilebesiran, for the management of hypertension. ALN-HSD, for non-alcoholic steatohepatitis (NASH). Fitusiran, addressing hemophilia and various rare bleeding disorders. Inclisiran, developed to treat hypercholesterolemia. Lumasiran, for advanced PH1 and recurrent kidney stones. Vutrisiran, currently in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals maintains strategic alliances with several key players in the industry. It collaborates with Regeneron Pharmaceuticals, Inc. on the discovery, development, and commercialization of RNAi therapeutics for ocular and CNS targets. Another significant partnership exists with Sanofi Genzyme, focusing on the broader development and commercialization of RNAi treatments. Furthermore, the company holds licensing and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. The company was established in 2002 and operates from its headquarters in Cambridge, Massachusetts.
www.alnylam.comNo one on the platform currently holds 0HD2.L.
No tracked institution reports a position in 0HD2.L as of their last filing.
No one on the platform has traded 0HD2.L yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 20.9% | — | — | — | ||
| Rev. Growth % | 65.2% | 49.8% | ||||
| Profit Margin % | 8.4% | -47.6% | -324.8% | |||
| Free Cash Flow Margin % | 12.5% | -26.2% | -271.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $5.5B | +45.6% | $6.67 | $6.01–$7.59 | — | 1 |
| 2027 | $6.9B | +26.9% | $10.08 | $9.08–$11.46 | — | 1 |
| 2028 | $8.3B | +19.6% | $12.51 | $11.27–$14.23 | — | 1 |
| 2029 | $9.3B | +12.5% | $14.37 | $12.95–$16.35 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.63 | $1.21 | -25.8% |
| 2026-04-30 | $0.87 | $1.51 | +73.2% |
| 2026-02-12 | $1.16 | $0.82 | -29.3% |
| 2025-10-30 | $0.56 | $1.83 | +226.2% |
| 2025-07-31 | $-0.54 | $-0.51 | +6.7% |
| 2025-05-01 | $-0.89 | $-0.44 | +50.6% |
| 2025-02-13 | $-0.59 | $-0.65 | -9.6% |
| 2024-10-31 | $-0.92 |
| $-0.87 |
| +5.3% |
| +0.67% |
| $40.3B |
| — |
| 0JAV.LInsmed Incorporated | $120.25 | -4.21% | $26.1B | — |
| 0JDM.LIQVIA Holdings Inc. | $271.00 | +1.98% | $45.7B | — |
Source: Financial Modeling Prep · peers by sector/industry